Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion

Pharmacotherapy. 2003 Aug;23(8):988-91. doi: 10.1592/phco.23.8.988.32878.


Study objective: To assess the pharmacokinetics of meropenem administered as a 3-hour infusion.

Design: Randomized, crossover, open-label study.

Setting: Clinical research center.

Subjects: Six healthy adult male volunteers.

Intervention: Each subject received meropenem 0.5 or 2 g every 8 hours as a 3-hour infusion for three doses and then crossed over to the other dosage regimen.

Measurement and main results: Pharmacokinetic parameters of both regimens were compared, and no significant differences between 0.5- and 2-g doses for the dose-independent parameters (half-life, clearance, and volume of distribution at steady state) were observed. The regimens displayed dose proportionality and were consistent with that of a traditional 0.5-hour infusion. The 3-hour infusion optimized the pharmacodynamic profile of meropenem and worked within the constraints of stability at room temperature stability.

Conclusion: Prolonging the percentage of time above the minimum inhibitory concentration is a feasible option with meropenem; however, further studies are needed to quantify how this increase translates to efficacy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / blood
  • Anti-Bacterial Agents / pharmacokinetics*
  • Cross-Over Studies
  • Humans
  • Infusions, Intravenous
  • Male
  • Meropenem
  • Middle Aged
  • Thienamycins / administration & dosage
  • Thienamycins / blood
  • Thienamycins / pharmacokinetics*
  • Time Factors


  • Anti-Bacterial Agents
  • Thienamycins
  • Meropenem